Let's talk medical research

As we move into 2024, we’d like to take a moment to highlight some of the significant achievements from the past year. Throughout 2023, we were able to reach more patients, work with more sponsors, and expand our business offerings in meaningful ways — and the impact we had serves as a great reminder of why we do what we do. In the infographic below, we’re delving deeper into the statistics that ...

One of the most important results of the work we do at Antidote is directly impacting the lives of patients — and getting to hear their stories is a constant reminder of why we do what we do.

Though clinical trial patient recruitment is an integral part of the medical research process, it is often one of the most difficult aspects of conducting a study. There are various reasons for this challenge, and among them is the widespread existence of misconceptions about participating in research that many patients may see as a barrier to entry.

While the primary goal of clinical trials is to help identify potential new treatments that improve people's health and save lives, it's the unfortunate truth that the patient experience is often not prioritized. This discrepancy becomes evident in industry findings, highlighting a substantial disparity between the services patients want from pharmaceutical companies compared to what they ...

The latest episode of Antidote’s quarterly podcast series Talk of the Towne is available now! Talk of the Towne is focused on bridging the gap between clinical discussion and patient centricity, hosted by Antidote’s Senior Clinical Informatics Manager, Dr. Richard Towne, PharmD.

Because Antidote’s key focus is connecting patients to clinical trials, hearing directly from individuals serves as a great reminder of why we do what we do. One patient we’ve had the pleasure of speaking with is Linda VandeVrede, a former high-tech PR executive who shared her story of chronic pain, clinical trials, and personal experience.

Early breast cancer is a specific diagnosis that occurs when cancerous cells have not yet spread from the breast or lymph nodes to other parts of the body. For a recent medical study, a client approached us to recruit patients who had received this diagnosis within the past 5 years to participate in a medical records registry.

Achondroplasia, a term meaning “without cartilage formation,” is a genetic disorder leading to disproportionate short stature. Sometimes called achondroplastic dwarfism or ACH, this condition has few treatment options and no known cure. However, individuals diagnosed with this condition can typically lead fulfilling, healthy lives with proper management.

Successfully randomizing participants into a clinical trial involves more than just recruiting through advertising outreach. Reaching individuals is part of the equation, but the patient enrollment process spans a much longer journey. That’s why Antidote provides comprehensive referral management services. Our full-service model reduces site burden and improves the patient experience, ultimately ...